ABIFINA
CONTATO
ASSOCIE-SE
LOGIN
  • Sobre
    • Quem somos
    • Código de Conduta Ética
    • Comitês
    • Estatuto Social
    • Estrutura organizacional
    • Galeria dos Presidentes
    • História
    • Segmentos da Química Fina
  • Prêmios
    • Prêmio Alcebíades de Mendonça Athayde
    • Prêmio Denis Barbosa
  • Associados
  • Notícias
    • ABIFINA na mídia
    • Associado em foco
    • Acontece na ABIFINA
    • Outras Notícias
  • Eventos
  • Produtos e serviços
    • ABIFINA Divulga
    • Clipping Diário de Notícias
    • Estatísticas
    • Centro de Monitoramento de Patentes
      • MPP Agro
      • MPP BIO
      • MPP Cannabis
      • MPP FDA
      • MPP FDA Biossimilares
      • MPP Saúde Animal
      • MPP SUS
    • Observatório de Ilegais
    • Panorama Regulatório Internacional
    • Propriedade Intelectual
      • Processo Administrativo de Nulidade (PAN)
      • Redação de Patentes
      • Relatórios de Patenteabilidade
      • Subsídios Técnicos
    • Resumo Semanal
  • Publicações
    • Revista FACTO
    • Todas as publicações
CONTATO

Repositório Covid-19

19/09/2022

Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein

Significance

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection requires fusion of viral and host membranes, mediated by the viral...

18/09/2022

Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy

Abstract

Coronavirus disease 2019 (COVID-19) remains a major public health concern, and vaccine unavailability, hesitancy, or failure underscore the need...

17/09/2022

A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response

Serological tests for SARS-CoV-2 specific antibodies can used for public health surveillance and vaccine development.•

17/09/2022

Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch

Abstract

The effectiveness of bebtelovimab in real-world settings has not been assessed. In this retrospective cohort study of 3607 high-risk...

17/09/2022

A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant

Abstract

The recently emerged Omicron (B.1.1.529) variant has rapidly surpassed Delta to become the predominant circulating SARS-CoV-2 variant, given the...

16/09/2022

A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Abstract

The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known.

16/09/2022

Use of low molecular weight heparin and hemoglobin fall in COVID-19 patients: A STROBE-compliant study

Abstract

In patients with coronavirus disease 2019 (COVID-19), anticoagulation was suggested as a mitigating strategy. However, little research has been...

14/09/2022

Consensus docking and MM-PBSA computations identify putative furin protease inhibitors for developing potential therapeutics against COVID-19

Abstract

The coronavirus disease 2019 (COVID-19) is a pandemic that has severely posed substantial health challenges and claimed millions of...

14/09/2022

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Summary

Background

BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals...

12/09/2022

Spatial and temporal dynamics of SARS‐CoV‐2: Modeling, analysis and simulation

Propose a novel reaction-diffusion viral infection model to characterize the infection process.•

12/09/2022

Zinc and COVID-19: Immunity, Susceptibility, Severity and Intervention

Abstract

12/09/2022

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

Summary

Background

BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals...

  • « anterior
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 38
  • 39
  • 40
  • 41
  • próxima »
  • Sobre
  • Associados
  • Notícias
  • Eventos
  • Estatísticas
  • Publicações
  • Contato
  • Política de Privacidade
Av. Churchill, 129 • Sala 1201 • Centro • Rio de Janeiro • RJ
+55 21 3125-1400 [email protected]

Todos os direitos reservados © 2025 - ABIFINA

Desenvolvido por Conceito Comunicação Integrada
Login
Esqueci a senha